Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Analysis of Δ9-Tetrahydrocannabinol and Cannabidiol in Commercial Suk-Saiyasna Herbal Remedy: Applying Hansen Solubility Parameters for Sample Extraction to Ensure Regulatory Compliance.

IF 4.3 3区医学 Q2 CHEMISTRY, MEDICINAL

Pharmaceuticals Pub Date : 2024-11-08 DOI:10.3390/ph17111502

Suwimon Sumontri, Wanna Eiamart, Sarin Tadtong, Weerasak Samee

{"title":"Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Analysis of Δ9-Tetrahydrocannabinol and Cannabidiol in Commercial Suk-Saiyasna Herbal Remedy: Applying Hansen Solubility Parameters for Sample Extraction to Ensure Regulatory Compliance.","authors":"Suwimon Sumontri, Wanna Eiamart, Sarin Tadtong, Weerasak Samee","doi":"10.3390/ph17111502","DOIUrl":null,"url":null,"abstract":"Background: Suk-Saiyasna is a traditional Thai herbal remedy that comprises 12 distinct herbs. Among these, cannabis leaves constitute 12 of the total 78 components in this formulation. This study specifically examines the portion of the cannabis plant, which accounts for approximately 15.8% of the overall herbal composition used in the entire remedy. According to the Thailand Narcotics Act of 2022, the Δ9-tetrahydrocannabinol (Δ9-THC) concentration in herbal extracts must not exceed 0.2% by weight. This study aims to quantify the levels of Δ9-THC and cannabidiol (CBD) in commercial Suk-Saiyasna products.Methodology: This research utilizes Hansen Solubility Parameters (HSPs) to identify the optimal solvent for ultrasonic extraction, thereby maximizing cannabinoid yield. An advanced method was developed employing ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), compliant with AOAC standards to meet regulatory guidelines. The method validation emphasized specificity, linearity, sensitivity, accuracy, and precision.Results: Dichloromethane was chosen due to its favorable HSP values, enabling highly efficient extraction of Δ9-THC and CBD, achieving recovery rates of over 99.9% after the second extraction. This investigation benefits from the accuracy of the UHPLC-MS/MS technique in quantifying cannabinoids in commercial products, with Δ9-THC concentrations observed between 0.00231% and 0.14218%, and CBD concentrations ranging from 0.00002% to 0.01541%, all remaining below the legal limit.Conclusions: The variability in cannabinoid concentrations among various commercial products highlights the need for standardization in the herbal industry. This finding underscores the critical role of rigorous quality control measures in ensuring the safety and efficacy of cannabis-derived products.","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"17 11","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph17111502","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Suk-Saiyasna is a traditional Thai herbal remedy that comprises 12 distinct herbs. Among these, cannabis leaves constitute 12 of the total 78 components in this formulation. This study specifically examines the portion of the cannabis plant, which accounts for approximately 15.8% of the overall herbal composition used in the entire remedy. According to the Thailand Narcotics Act of 2022, the Δ9-tetrahydrocannabinol (Δ9-THC) concentration in herbal extracts must not exceed 0.2% by weight. This study aims to quantify the levels of Δ9-THC and cannabidiol (CBD) in commercial Suk-Saiyasna products.

Methodology: This research utilizes Hansen Solubility Parameters (HSPs) to identify the optimal solvent for ultrasonic extraction, thereby maximizing cannabinoid yield. An advanced method was developed employing ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), compliant with AOAC standards to meet regulatory guidelines. The method validation emphasized specificity, linearity, sensitivity, accuracy, and precision.

Results: Dichloromethane was chosen due to its favorable HSP values, enabling highly efficient extraction of Δ9-THC and CBD, achieving recovery rates of over 99.9% after the second extraction. This investigation benefits from the accuracy of the UHPLC-MS/MS technique in quantifying cannabinoids in commercial products, with Δ9-THC concentrations observed between 0.00231% and 0.14218%, and CBD concentrations ranging from 0.00002% to 0.01541%, all remaining below the legal limit.

Conclusions: The variability in cannabinoid concentrations among various commercial products highlights the need for standardization in the herbal industry. This finding underscores the critical role of rigorous quality control measures in ensuring the safety and efficacy of cannabis-derived products.

查看原文本刊更多论文

商用 Suk-Saiyasna 草药中的Δ9-四氢大麻酚和大麻二酚的超高效液相色谱-串联质谱分析：应用汉森溶解度参数进行样品提取以确保符合法规要求。

背景介绍Suk-Saiyasna 是一种传统的泰国草药疗法，由 12 种不同的草药组成。其中，大麻叶占该配方总 78 种成分中的 12 种。本研究专门研究了大麻植物的部分，该部分约占整个药方所用草药成分的 15.8%。根据《泰国 2022 年麻醉品法》，草药提取物中的Δ9-四氢大麻酚（Δ9-THC）浓度不得超过 0.2%（按重量计）。本研究旨在量化商业 Suk-Saiyasna 产品中的Δ9-THC 和大麻二酚 (CBD) 含量：本研究利用汉森溶解度参数（HSP）来确定超声波萃取的最佳溶剂，从而最大限度地提高大麻素产量。研究人员采用符合 AOAC 标准的超高效液相色谱-串联质谱法（UHPLC-MS/MS）开发了一种先进的方法，以满足监管准则的要求。方法验证强调了特异性、线性、灵敏度、准确度和精密度：选择二氯甲烷是因为它具有良好的 HSP 值，能够高效萃取 Δ9-THC 和 CBD，第二次萃取后的回收率超过 99.9%。这项调查得益于超高效液相色谱-质谱/质谱技术在量化商业产品中大麻素含量方面的准确性，观察到的 Δ9-THC 浓度在 0.00231% 到 0.14218% 之间，CBD 浓度在 0.00002% 到 0.01541% 之间，均低于法定限度：各种商业产品中大麻素浓度的差异凸显了草药行业标准化的必要性。这一发现强调了严格的质量控制措施在确保大麻衍生产品的安全性和有效性方面的关键作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

6.10

自引率

4.30%

发文量

1332

审稿时长

6 weeks

期刊介绍： Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.